An Article In The Lancet Reported Positive Data From Phase 1-2 Trial Of MDV3100 for men with Advanced Prostate Cancer (4/15/10)

It was announced today that the phase I/II trial of MDV3100 demonstrated positive results. MDV3100 is a novel triple-acting oral androgen receptor antagonist, the common antagonist most of us are familiar with today is Casodex. These results were published in the online April 15 version of The Lancet. […]